Review
Oct 2026
Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration.
The emerging role of repurposed low-cost therapies, particularly hydroxyurea and thalidomide, as disease-modifying options in resource-limited settings are discussed and opportunities to democratise access to curative gene therapies through technological developments, decentralised manufacturing, regional collaboration...
Hanny T. Al-Samkari, F. Aboobacker, B. Andemariam et al.
· The Lancet Haematology · 2 citations